Literature DB >> 12566814

Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.

Ashok K Hemal1, Anurag Khaitan, Amit K Dinda, Narmada P Gupta, Amlesh Seth, P N Dogra, Gulam Nabi.   

Abstract

INTRODUCTION: The objective of the study was to determine the pattern of p53 expression in patients with muscle invasive bladder cancer treated with cystectomy and to assess the prognostic value of p53 expression in this group of patients.
MATERIALS AND METHODS: We retrospectively analyzed data of 100 patients who underwent cystectomy for invasive transitional cell carcinoma of the urinary bladder. These patients were seen at 3-monthly intervals during the first 2 years, 6-monthly in the third year, and yearly thereafter. Immunohistochemical analysis for p53 was done on paraffin-fixed tissues with DO-7 antibodies. The tumours with >30% cells staining for p53 proteins were considered p53 positive.
RESULTS: There were 95 males and 5 females with a mean age of 54 years. Two patients died in the perioperative period and were excluded from analysis. Over a median follow-up period of 2 years (range 3 months to 10 years) 62 patients are alive without disease while 36 had relapse and of these, 31 have died. The p53 expression was significantly related to stage and grade of the tumour. p53-negative tumours were more likely to be organ confined and of lower grade as compared to p53-positive tumours. The stage of tumour was significantly related to outcome but grade and p53 immunohistochemistry did not provide any prognostic information.
CONCLUSIONS: p53 immunostaining was positive in 57% of muscle invasive urinary bladder tumours. The p53 positivity correlated well with the stage and grade of the disease, whereas it has no additional prognostic value. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566814     DOI: 10.1159/000067703

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Transitional Cell Carcinoma of Urinary Bladder Manifesting as Extensive Retroperitoneal and Axillary Lymph Node Metastasis: An Extremely Rare Case Scenario Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography Scan.

Authors:  Abhishek Purkayastha; Neelam Sharma; Rekha Vashisth; Braj Kishore
Journal:  Indian J Nucl Med       Date:  2017 Oct-Dec

2.  Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients.

Authors:  Rania Bakry; Mohamed I El-Sayed; Hesham M Hamza; Khaled H Hassan
Journal:  Oncol Lett       Date:  2015-11-17       Impact factor: 2.967

3.  Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer.

Authors:  Farha A El-Chennawi; Fatma A Auf; Shereen S Metwally; Youssef M Mosaad; Atallah A Shaaban; Mahmoud Abdo El-Baz; Ziyad E Tawhid; Zakaria F Lotfy
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

4.  Identification of methylated genes associated with aggressive bladder cancer.

Authors:  Carmen J Marsit; E Andres Houseman; Brock C Christensen; Luc Gagne; Margaret R Wrensch; Heather H Nelson; Joseph Wiemels; Shichun Zheng; John K Wiencke; Angeline S Andrew; Alan R Schned; Margaret R Karagas; Karl T Kelsey
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

5.  P53 and cancer-associated sialylated glycans are surrogate markers of cancerization of the bladder associated with Schistosoma haematobium infection.

Authors:  Júlio Santos; Elisabete Fernandes; José Alexandre Ferreira; Luís Lima; Ana Tavares; Andreia Peixoto; Beatriz Parreira; José Manuel Correia da Costa; Paul J Brindley; Carlos Lopes; Lúcio L Santos
Journal:  PLoS Negl Trop Dis       Date:  2014-12-11

6.  Transitional Cell Carcinoma of the Bladder Manifestating as Malignant Lymphoma with Generalized Lymphadenopathy.

Authors:  Venkat Pavan Kancharla; Frederick A Gulmi; Aref Agheli; Michael Degen; Arash Gohari; Ming Jiang; J C Wang
Journal:  Case Rep Oncol       Date:  2010-04-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.